• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Trump slump: Report says FDA enforcement is way down

Trump slump: Report says FDA enforcement is way down

July 3, 2019 By Brad Perriello

FDAEnforcement at the FDA reportedly slumped after President Donald Trump took office, with warning letters off by a third and medical device warnings off by two-thirds.

From the January 2017 inauguration through May 22, the FDA issued 1,033 warning letters, a -32.6% decline compared with the most recent equivalent from the Obama administration, Science magazine reported.

And the federal safety watchdog’s Center for Devices & Radiological Health and district offices in Philadelphia, Florida, and New York are down by more than two-thirds – two district offices haven’t put out a warning in more than two years, according to the magazine. And the FDA sent significantly fewer warning letters in the second year of the Trump administration than in the first.

“Those who think the Trump administration has not succeeded in its deregulatory efforts ought to look at these data,” former FDA executive Peter Lurie, now executive director of the Center for Science in the Public Interest, told Science. “Industry may well take the message from this that the cop is not on the beat as often.”

“FDA’s power to enforce its requirements is an important part of how it achieves its public health mission,” added Ohio State University law professor Patricia Zettler, a former FDA attorney. “If FDA is not using that power, it sends a signal that violations will be tolerated.”

Former FDA commissioner Dr. Scott Gottlieb said the agency was “pretty aggressive” in enforcing its regulations.

“We were pretty aggressive,” Gottlieb told the magazine via email. “I don’t think you can paint us with a political narrative – that just because we were a Republican administration, somehow we must have ratcheted down enforcement activity. We didn’t.”

The FDA improved enforcement efficiency and expanded field resources during his tenure there, he added in an interview, with stem cells, vaping, dietary supplements, homeopathy, opioids, and generic drugs coming under focus. Warning letters and other such actions are imperfect enforcement measures, Gottlieb argued, according to the report.

“Sometimes the actions we take are visible, like warning letters (or) recalls,” the FDA said in a prepared statement sent to Science. “At other times, our actions to protect consumers are less discernible, but equally vital.”

“The FDA’s enforcement role is extremely important,” former acting commissioner Joshua Sharfstein told the magazine. “If the FDA isn’t doing enforcement, nobody’s doing enforcement.”

Filed Under: Featured, Food & Drug Administration (FDA), Regulatory/Compliance

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy